Michelle L. Mellion - Jul 12, 2024 Form 4 Insider Report for PepGen Inc. (PEPG)

Role
Chief Medical Officer
Signature
/s/ Noel Donnelly, as Attorney-in-Fact
Stock symbol
PEPG
Transactions as of
Jul 12, 2024
Transactions value $
-$71,759
Form type
4
Date filed
7/16/2024, 04:46 PM
Previous filing
Jul 3, 2024
Next filing
Jul 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEPG Common Stock Options Exercise $33.6K +3.29K $10.21 3.29K Jul 12, 2024 Direct F1
transaction PEPG Common Stock Sale -$59.3K -3.29K -100% $18.04 0 Jul 12, 2024 Direct F1, F2
transaction PEPG Common Stock Options Exercise $60.2K +5.9K $10.21 5.9K Jul 16, 2024 Direct F1
transaction PEPG Common Stock Sale -$106K -5.9K -100% $18.00 0 Jul 16, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEPG Stock Option (Right to Buy) Options Exercise $0 -3.29K -4.13% $0.00 76.3K Jul 12, 2024 Common Stock 3.29K $10.21 Direct F1, F4
transaction PEPG Stock Option (Right to Buy) Options Exercise $0 -5.9K -7.73% $0.00 70.4K Jul 16, 2024 Common Stock 5.9K $10.21 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 19, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.